---
title: "Cytek Biosciences, Inc. (CTKB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CTKB.US.md"
symbol: "CTKB.US"
name: "Cytek Biosciences, Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T07:09:26.420Z"
locales:
  - [en](https://longbridge.com/en/quote/CTKB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CTKB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CTKB.US.md)
---

# Cytek Biosciences, Inc. (CTKB.US)

## Company Overview

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [cytekbio.com](https://cytekbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.55)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 33 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.61% |  |
| Net Profit YoY | -557.63% |  |
| P/B Ratio | 1.41 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 461039035.59 |  |
| Revenue | 204171000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -20.93% | E |
| Profit Margin | -36.25% | E |
| Gross Margin | 48.16% | B |
| Revenue YoY | 3.61% | C |
| Net Profit YoY | -557.63% | E |
| Total Assets YoY | -6.94% | D |
| Net Assets YoY | -13.69% | E |
| Cash Flow Margin | 9.86% | D |
| OCF YoY | 3.61% | C |
| Turnover | 0.44 | C |
| Gearing Ratio | 27.05% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Cytek Biosciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.61%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-557.63%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.41",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "461039035.59",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "204171000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-20.93%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-36.25%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "48.16%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "3.61%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-557.63%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.94%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-13.69%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "9.86%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "3.61%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.44",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.05%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.23 | 42/59 | - | - | - |
| PB | 1.41 | 18/59 | 1.73 | 1.44 | 1.20 |
| PS (TTM) | 2.26 | 19/59 | 3.16 | 2.71 | 2.29 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 25% |
| Overweight | 1 | 25% |
| Hold | 2 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.57 |
| Highest Target | 7.50 |
| Lowest Target | 4.75 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CTKB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CTKB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CTKB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CTKB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**